MANAGEMENT PRESENTATION - Lidds...15 Source: (1) World Cancer Research Fund, 2018, (2) Cancer...

1

MANAGEMENT PRESENTATION

Monica Wallter, [email protected]

November 2018

2

Table of content

1. Introduction to LIDDS

2. NanoZolid® with 2-HOF – Prostate cancer

3. NanoZolid® with cytostatics (DTX)

4. NanoZolid® for immunotherapy (IO)

5. NanoZolid® with STING-agonist

A. Appendix

6. NanoZolid® with TLR9 agonist

3

in brief

Founded

HQ

Employees

Listing venue

2003

Uppsala, Sweden

~10

Nasdaq First North

LIDDS is a Swedish-based pharmaceutical company developing injectable drugs for cancer and other diseases based on our unique proprietary NanoZolid® technology. NanoZolid® helps solve some of the main problems with the way drugs work in the body and which

affect patient quality of life.

NanoZolid® enables the controlled, long-term release of drugs for up to six months. NanoZolid® can be combined with traditional small as

well as with larger molecules.

LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development in pre-clinical projects in

clinical phase for cytostatics and immunoactive agents.

Unique and patented technology platform

Combined with anti-androgen Liproca® Depot for treatment of localized prostate cancerStatus: Phase IIb

Combined with cytostaticNanoZolid® combined with Docetaxel (DTX)Status: Phase I study started Q1 2019

Combined with immunotherapyNanoZolid® combined with a range of IO agents in development Status: Ongoing preclinical package

ONE PLATFORM PROJECTS

Combined with STING-agonistNanoZolid® combined with STING-agonists (STING)Status: Pre-clinical full program ongoing

Combined with TLR9-agonistNanoZolid® combined with TLR9-agonistsStatus: Pre-clinical full program ongoing

4

IDEAL DRUG DELIVERY PROPERTIES

NanoZolid® is an innovative drug delivery platform

▪ NanoZolid® is a safe, flexible and functional method of delivering drugs.

▪ NanoZolid® provides effective, controlled and tailor made release of drugs with small or larger size.

▪ NanoZolid® has a broad drug formulation capability and can be formulated with substances of very different molecular characteristics.

▪ The NanoZolid® matrix with drug is reabsorbed completely in the tissue due to its water solubility.

<1month

NanoZolid® delivers a fast release of active drugs where required

1-3months

NanoZolid® can be used for the intermediate release of active drugs

3-6months

NanoZolid® provides for longer drug release times where it is needed

THE CONTROLLED RELEASE OF DRUG COMPOUNDS CAN BE TAILORED TO THE NEEDS OF THE PATIENT, DISEASE AND DRUGS BEING USED:

•

5

The platform can be used for a wide range of applications

NanoZolid® has many applications and can be tailored to the needs of the patient, the disease being treated and the drug formulations being used.

THE TECHNOLOGY IS CLINICALLY PROVEN WITH VALIDATED EFFECTS DURING 6 MONTHS IN PHASE II CLINICALS

Intratumorally

NanoZolid® provides a high level of efficiency by allowing cancer drugs to be injected directly into the tumor.

Controlled release results in higher local impact and reduced severe systematic side effects for patients.

Subcutaneously

NanoZolid® can be injected subcutaneously allowing for sustained release of active drugs over an extended period of time for systematic impact and improved compliance.

•

✓

6

Strong benefits for both patients and pharma industry

PHARMA INDUSTRYPATIENTS

Improved efficacy‒ Higher drug effects in diseased area

Less side effects‒ Minimal and controlled concentration of drug systemically –

improving Quality Of Life

Less injections‒ The sustained and controlled drug release gives higher

compliance and Quality Of Life

Improved products‒ NanoZolid® enables higher efficiency, compliance and reduced

side effects

Prolonged patent protection‒ NanoZolid technology maintains competiveness with patents

until 2037‒ Opportunity for Life Cycle Management

Re-open closed projects ‒ Previously closed projects due to severe side effect or too fast

release of the drug can be re-opened

7

A safe, flexible and functional method of delivering drugs as a long-acting depot

▪ Intratumoral drug delivery enables a high drug load and efficacy in cancer tumors combined with small risks for systemic adverse effects - quality of life for patients

▪ Effectively reduces the number of treatments and adverse effects which in turn reduces patient discomfort, improves compliance and reduces costs

NanoZolid® is formulated with APIs with different size & characteristics:

▪ Anti-androgens: 2-hydroxy-flutamide & other anti-androgen drugs

▪ Cytotoxic drugs: Docetaxel, Doxorubicin, Cisplatin, Temozolamide & other cytostatics

▪ Immuno-active agents: STING-agonists, TLR- agonists, IDO1-inhibitors

▪ Hormones: i.e Testosterone

▪ Glucocorticoids

▪ Antihistamines

▪ Polypeptides

NanoZolid® – a clinically validated technology

8

NANOZOLID® PATENT PORTFOLIO

8 patent families & 90 patents

ANTI ANDROGENS – PROSTATECANCERNZ-2-HOF

Liproca® Depot, 2-hydroxy-flutamide

CYTOTOXICS – SOLID TUMORSNZ-DTX , NZ-DOX etc

Docetaxel, doxorubicin and other cytotoxic drugs

IMMUNO-ONCOLOGYNZ-IO-STING, NZ-IO-TLR9, NZ-IO-003, NZ-IO-004

Immuno-active molecules

EXTERNAL PARTNERSHIP – NZA wide range of indications are possible

1

2

3

4

Patent protection until year 2037

9

2 3 4

LIDDS’ business strategy is to use the NanoZolid® technology for three purposes: in-house drug development, for outlicensing to other pharma companies for use in their development of new drugs, and as a tool for life cycle management of established medicines.

LIDDS’ business model

NANOZOLID® TECHNOLOGY

INNOVATIVE PRODUCT

LICENSE AGREEMENTS

Validated in Phase II enables optimal product design

Local injection Strategic partnershipsTypically in pre-clinical phase or

Phase I/II

1

PROVEN DRUG SUBSTANCE

Off patent or new API

10

Overview of current development pipeline

PROJECT TARGET FEASIBILITY PRECLINICAL PHASE I / II PHASE IIbOUT-LICENSING &

AGREEMENTS

In-house drug development

NZ-2-HOF Prostate cancer 2017-2019Out-licensed to China - Licensing to ROW during / after Phase IIb

NZ- DTX Malignant tumors ✓ Out-licensing after Phase I

NZ-IO- STING Malignant tumorsOut-licensing after preclinical phase

NZ-IO-TLR9 Malignant tumors Out-licensing after Phase I

NZ-IO-003-004 Malignant tumors

NZ-DOX Malignant tumors

✓ ✓ ✓

✓ ✓

✓ ✓

✓

✓

✓

NanoZolid® constitutes the bedrock for building a broad portfolio of pharmaceutical projects,

which diversifies risk and provides good prospects for future revenue

✓

11

Table of content

Introduction to LIDDS





A. Appendix


2.

1.

12

▪ Clinical studies shows Liproca® Depot has enhanced effects at higher doses, without the hormonal side effects that are common with oral treatment.

▪ Phase I/II clinical trials with Liproca ®Depot is reported in 57 patients with good results on PSA biomarker, tumor tissue and prostate volume

▪ Industrial scale production - NZ-2-HOF at Recipharm

▪ LPC-004 status- Safety and tolerability confirmed afterPart I - entered into Part II in Q3/18

▪ Phase IIb study ongoing – results in mid 2019▪ Out-licensed to China▪ Out-licensing to ROW during / after Phase IIb

N Z - 2 - H O F

LIDDS treats prostate cancer locally

13

Side effects are fully avoided or significantly reduced

Treatment with LIDDS

LIDDS TARGETS ONLY THE ORGANALL BODY EXPOSED

Traditional systematic treatment

Chemical castration & anti androgen therapy side effects:▪ Loss of libido & Erectile dysfunction▪ Hot flushes ▪ Gynaecomastia and breast pain ▪ Increase in body fat & Muscle wasting▪ Anemia ▪ Decrease in bone mineral density▪ Cognitive decline

LIDDS’ drug candidate is injected directly into the tumour▪ Provides a pre-determined, controlled and long-term effect on

the tumour

N Z - 2 - H O F

Local treatment strategy

14

N Z - 2 - H O F

n = 60 patients with local prostate cancer

PSA reduction %: LIDDS dose/effect prediction in Phase Ilb study based on previous studies

LPC-002 (700mg) 6 months

LPC-0031 (900mg) 2 months

LPC-0032 (1,700mg) 2 months

LPC-004 (2,000mg) simulated

LPC-004 (4,000mg) simulated

15 Source: (1) World Cancer Research Fund, 2018, (2) Cancer Research UK, (3) Prostate Smart, (4) PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023.

1,300,000Patients diagnosed per year1

Every fifth manWill be diagnosed 20302

250,000Dies every year3

5 % patient share

Liproca® Depot yearly sales:

≥ $1,000m

Global prostate cancer market

$8.3bnin 20234

N Z - 2 - H O F

The global prostate cancer drug market is estimated to ≥ 8 billion USD in 2022

16

Table of content






A. Appendix


1.

3.

17

Preclinical study shows that NZ-DTX is as efficient as systemic docetaxel in reducing tumor growth but with far less side effects

▪ Docetaxel is a commonly used chemotherapy: Breast, head and neck, gastric, prostate and non small cell lung cancer (NSCLC).

▪ Monotherapy or in combination with different drugs to optimize effects:

- Neoadjuvant NZ-DTX before surgery/radiation- Treatment at diagnosis of tumor- Palliative therapy - Combination with systemic drugs, e.g. cytostatics / I-O- Phase I Study started 2019, Scandinavian sites

N Z - DT X

Lung cancer and solid tumors

18

N Z - DT X

230,000Diagnosed in US2

310,000Diagnosed in

EU283

Lung cancer

$37bn global market1

CAGR of

>13% until 20231

>540,000 individuals are diagnosed with lung cancer in the EU28 and the US

Promising potential of a focal treatment with docetaxel in non-small cell lung cancer & solid tumors

Source: (1) Lung Cancer Market Research Report – Global Forecast to 2023; (2) American Cancer Society, 2018; (3) Lung Cancer Europe, GLOBOCAN 2012.

19

Table of content






A. Appendix


1.

4.

20

Immuno Oncology (IO) – a major opportunity for LIDDS

Providing an intratumoral sustained release immuno-modulating treatment that increasesresponse rates while minimizing side-effects

Several preclinical projects ongoing, includingNZ-STING and NZ-TLR9

N Z - I O

21

Local treatmentIntratumoral injection with Nanozolid formulated drug to stimulate immunity

Distal effectsSystemic anti-tumorimmunity in non-injected tumors

INTRATUMORAL INJECTION

N Z - I O

Intratumoral Immunotherapy: Acting locally for systemic efficacy

22

Immunotherapy

combination

Immunotherapy

monotherapy

Traditional

therapies

Control

TIME FROM TREATMENT

PE

RC

EN

TA

GE

SU

RV

IVA

L

Increased response rates and long-term survival

Increased long-term survival

N Z - I O

Providing a local immuno-modulating treatment that increases response rates while minimizing side-effects

“Emphasis on combination strategies continues to resonate throughout the

scientific community and has been highlighted at several recent

conferences. During Immunotherapy World (January 2017), it was even

stated that the field would ultimately move “entirely” to combination

therapies.”- Erin Newburn MS, PhD

The future of these drugs is in combination strategies […] And, most

of the data that are leaking out of ASCO and other meetings are looking

at combinations. - Benjamin P. Levy, Clinical Director of

Medical Oncology at Kimmel Cancer Centre

COMBINATION THERAPY IS THE FUTURE

23

N Z - I O

Intratumoral Immunotherapy: Leveraging the potential with NanoZolid®

24

▪ Local, intratumoral immunotherapy enables the use of potent immune stimulating agents (e.g. STING agonists, TLR-agonists) that can be combined with check point inhibitors or other IO drugs

▪ Local immune stimulation can induce systemic anti-tumor immunity

▪ Possibility to turn “cold tumors” into “hot tumors” that can respond to checkpoint inhibition treatment

▪ NanoZolid ® formulated local acting immunotherapies offers greater treatment options, higher efficacy, increased patient friendliness and greater healthcare penetration

▪ Enables treatment of deep-lying tumors which can be more immunologically representative of primary and metastasizing tumors (e.g. lung, brain, colon, prostate, gastric cancers etc.)

▪ NanoZolid ® technology enables the potential of intratumoralimmuno-therapy by providing a practical, efficacious and patient-friendly drug delivery technology

N Z - I O

Intratumoral Immunotherapy

25

Table of content






A. Appendix


1.

5.

26

STING - Stimulator of interferon genes

▪ Highly promising agent for immune stimulation

▪ Local activation of STING in tumors leads to potent tumor regression

and systemic immunity

▪ Activators of STING have the potential to make more cancers respond

to immunotherapy

▪ Actively pursued by BMS, Merck, GSK, Novartis and others

▪ STING must be administered intratumorally due to severe systemic

side effects

N Z - S T I N G

NanoZolid® - STING (NZ-STING)

27

▪ STING agonist treatment is effective when administered in the right way

▪ For better safety:• A slow (and controlled) intratumoral release resulting in low risk

for systemic side effects• Fewer injections avoid risks for complications

▪ NanoZolid formulations makes STING agonists practical for treatment:• Single injection active up to several months• Especially important for tumors not suitable for multiple injections• NanoZolid depot is visible with x-ray and ultra sound equipment to

confirm correct injection• Reduced cost for treating hospitals• Better patient compliance and convenience

▪ Major commercial opportunity

N Z - S T I N G

Working hypothesis

28

Syngeneic preclinical animal models were used at a qualifiedEuropean CRO:

A single NZ-STING injection was equal or better to reduce tumorgrowth versus three repeated standard STING injections

▪ Verified efficacy in different syngeneic models

▪ Safe and well tolerated

▪ Potential to leverage NanoZolid® technology in highly competitive and promising field

▪ Patent application submitted for NZ-STING

N Z - S T I N G

NZ-STING- extensive preclinical programme

29

Table of content






A. Appendix


1.

6.

30

TLR9 agonist project ongoing and plan for Phase I

▪ LIDDS has performed pre-clinical studies with promising results using a TLR9 agonist formulated with NanoZolid®

▪ A preclinical programme is ongoing to broaden the results obtained to date

▪ Currently preparing for a Phase I clinical trial using NanoZolid® combined with a TLR9 agonist

▪ Planned start for clinical Phase I trial in 2020

▪ Major commercial opportunity ▪ The most relevant target cancers for the TLR9 project are head

and neck cancer, prostate cancer and lymphomas. These cancers are diagnosed in around 2 million patients each year.

N Z - I O - T L R 9

31

N Z - I O -S T I N G / T L R 9

ˣ Frequent injections

ˣ Superficial tumors

ˣ Limited patient population eligible

ˣ Limited tumor residence time

ˣ Includes high costs and resources in specialized hospitals

✓Up to once every 3 to 6 months

✓Superficial and deep-lying tumors

✓Greater options regarding treatment and including poor status patients

✓Long-term immune stimulation

✓Less costs and resources needed

Standard STING/TLR9-injection NanoZolid STING/TLR9 depot

Local immunotherapy with NanoZolid® provides several advantages vs standard injections

Vs.

32

Significant value inflection points ahead

EXPECTED Q3 2019 – Q4 2019EXPECTED Q1 2019 – Q2 2019

▪ Start of Phase I study NZ- DTX-001 and first patient in

▪ Preclinical research program NZ-IO-STING

▪ Preclinical studies NZ-IO- 002-004

▪ Status update of NZ-2HOF, LPC-004

▪ Organization Expansion

▪ Concluding the Phase IIb study

▪ Update on NZ-DTX-001

▪ Update of NZ-IO projects

▪ New NZ-projects

EXPECTED 2020

▪ Listing of the company’s shares on Nasdaq Stockholm’s Main Market

✓

33

Table of content






A. Appendix


1.

A.

34

Shareholder listShareholders as per 31 December 2018 Number of shares Capital Votes

Wikow Ventures AB (Lars Wikander) 1,955,048 8.48 % 8.46 %

Daniel Lifveredson through companies 1,914,393 8.30 % 7.63 %

Nyenburgh Holding B.V. 1,521,355 6.60 % 7.01 %

Bengt Sporre 923,567 4.01 % 4.01 %

Recipharm Venture Fund AB 714,285 3.10 % 3.10 %

Gunvald Berger 571,258 2.48 % 2.48 %

BWG Invest Sàrl (William Gunnarsson) 531,000 2.30 % 2.32 %

Henry Dunkers Donationsfond & Stiftelser 412,314 1.79 % 2.30 %

Hans Lennernäs with company 373,268 1.62 % 1.64 %

Arena Invest AB (Roberth Emanuelsson) 318,471 1.38 % 1.38 %

Sub total 9,234,959 40.06 % 40.06 %

Others 13,816,229 59.94 % 59.94 %

Total 23,051,188 100.0 % 100.0 %

SEK

>200million

Since LIDDS was founded in 2003, more than SEK 200 million has been invested into the company and the developmentof the NanoZolid® technology platform.

A. APPENDIX

35

Income statement

A. APPENDIX

(TSEK) Oct-Dec 2018 Oct-Dec 2017 Jan-Dec 2018 Jan-Dec 2017

Other sales 0 434 7,763 1,029

Gross income 0 434 7,763 1,029

Other external expenses -2,383 -1,561 -6,916 -4,588

Personnel expenses -994 -1,085 -3,150 -3,124

Impairment of intangible assets -1,577 0 -1,577 0

Total costs -4,954 -2,646 -11,643 -7,712

Operating profit -4,954 -2,212 -3,880 -6,683

Financial items 14 1 133 14

Profit for the period -4,940 -2,211 -3,747 -6,669

36

Balance sheet

A. APPENDIX

(TSEK) 2018-12-31 2017-12-31

ASSETS

Fixed assets

Capitalized development costs 123,002 101,091

Patent 12,746 13,189

Total intangible assets 135,748 114,280

Total tangible assets 50 0

Total fixed assets 135,798 114,280

Current assets

Short-term receivables 1,439 1,245

Cash and cash equivalents 26,139 15,286

Total current assets 27,578 16,531

Total assets 163,376 130,811

EQUITY AND LIABILITIES

Equity 158,517 127,250

Short-term liabilities 4,859 3,561

Total equity and liabilities 163,376 130,811

37

Cash flow statement

A. APPENDIX

(TSEK) Oct-Dec 2018 Oct-Dec 2017 Jan-Dec 2018 Jan-Dec 2017

Cash flow from the operating business -4,297 -1,345 -1,066 -10,715

Cash flow form investment activities -7,097 -4,066 -23,096 -14,079

Cash flow from financing activities 0 1,000 35,015 21,399

Cash flow for the period -11,394 -4,411 10,853 -3,395

Cash position at the beginning of the period 37,533 19,697 15,286 18,681

Cash position at the end of the period 26,139 15,286 26,139 15,286

38

JAN TÖRNELLChairman of the Board since 2015Holdings: 33,142 shares, 250,000 warrants

15 years of experience in executive roles in the pharmaceutical industry in various countries. Professor with medical background. CEO of Oncorena AB and AB Innoext. Former Vice President of Global Strategy for AstraZeneca Oncology & Infection. Professor of Physiology at the Sahlgrenska Academy. Chairman of Glactone Pharma AB and board member of Diaprost AB. Partners in P.U.L.S. and member of the investment committee. Born 1960.

DANIEL LIFVEREDSONBoard member since 2017Holdings: 1,759,492 shares, 200,000 warrants

INGALILL FORSLUND LARSSONBoard member since 2015Holdings: 10,000 shares, 125,000 warrants

M.Sc. in Engineering, Industrial Economy, Chalmers tekniska högskola in Gothenburg. CEO and owner of Excore AB, specialized in counseling in connection with corporate transactions in the segment of medium-sized companies. Long experience in international business. Daniel Lifveredson is engaged as a partner in several companies. Born 1976.

Economist with specialization in Marketing from the University of Uppsala. Leg. Midwife. Many years of sales and marketing responsibility in the pharmaceutical industry, incl. business responsibility for Urology, Global Marketing at Ferring Pharmaceuticals. several commercial roles at AstraZeneca incl. responsible for a number of product launches. Senior Consultant at LisbergExecutive Search and Boyden International. CEO of a private real estate and consulting company. Board experience from several life science companies. Born 1954.

Master’s degree in Economics from the School of Business, Economics and Law and Concordia University, Montreal. Active as VP Business Development & Global Marketing at the Swedish listed company Vitrolife since 2012. Maria Forss has for 20 years worked with product development, business development and marketing of pharmaceutical products in global roles at AstraZeneca, as well as in the virtual company DuoCort, where she as CEO and project managers had been instructed to take a new drug from clinical trials to regulatory approval and sales of the company. She has experience in product development of medicines from early phase to commercialization, and from several board positions in the pharmaceutical and medical technology companies. Born 1972.

MARIA FORSSBoard member since 2015Holdings: 18,100 shares, 150,000 warrants

ANDERS BJARTELLBoard member since 2015Holdings: 18,100 shares, 150,000 warrants

Professor and chief of urology at Skåne University Hospital since 2006. PhD in Medical cell research. European specialist degree in Urology. Visiting investigator at Memorial Sloan-Kettering Cancer Center in New York, 2005-2007. Associate Editor of European Urology, 2005-2012. Responsible for clinical trials in prostate cancer at the urology clinic SUS Malmö since 2007. National Principal Investigator for several new drugs for prostate cancer in recent years. Research group leader for urological cancer research at the Institute for Translational Medicine at Lund University. Published over 200 original scientific articles. H-index 39. Have experience in board work in European Urology, foundations and life science. Born 1959.

Board of directors

A. APPENDIX

39

Senior executives and management

MONICA WALLTERCEOHoldings: 20,019 shares, 125,000 warrants

International Diploma in Marketing & Economics from University of Lund, Sweden. Former CEO of Ellen AB (publ) from 2008 to 2014 and CEO of ProbiAB (publ) 2000-2003. Senior international management positions in Pharmacia between 1986-1995. Heading several business areas as Global Category Director at Pharmacia & Upjohn during 1996-2000.

BENGT NORVIKCFOHoldings: 33,274 shares, 25,000 warrants

Accountant from the University of Uppsala. Former CFO of Know IT AB (publ), Pargon AB and AB Upnod. Bengt runs his own business MarkettAffärsutveckling AB, which provides consulting services in economics and finance. Bengt has experience from both listed as start-ups in Life Science, IT industry and commerce.

STEFAN GRUDÉNDirector of pharmaceutical R&DHoldings: 500 shares, 25,000 warrants

Pharmacists, M.Sc. Pharm., From Uppsala University. 17 years experience in pharmaceutical research and development, including 15 years in senior services and Pharmacy Manager both Galenica and Orexo. Participated in the development of over 50 projects, of which more than a third have been upscaled.

NIKLAS AXÉNDirector of Biomaterials & DevicesHoldings: 70,000 shares, 25,000 warrants

M.Sc. Engineering Physics at Uppsala University, PhD and Associate Professor of Materials Science at Uppsala University. Niklas Axen has previously worked in product development at De Beers and Hemapure, and has been in charge of R & D including Cerbio AB, Doxa AB and AB OrtoWay.

MARTIN JOHANSSONHead of preclinical R&D in immunotherapyHoldings: 500 shares, 25,000 warrants

M.Sc. chemical engineering Lund University, Ph.D. and associate professor in organic chemistry at Lund University. 17 years of experience in medicinal chemistry and preclinical research and development. Formed Chief Scientific Officer with Respiratorius and senior research scientist at AstraZeneca Discovery R&D.. Project manager for Glactone Pharma.

A. APPENDIX

CHARLOTTA GAUFFINHead of Clinical Trial ManagementHoldings: 0 shares, 0 warrants

Master of Science M.Sc. and Ph.D. in organic chemistry from Uppsala University. About 20 years of experience in the pharmaceutical industry, within research and clinical development. Has held senior clinical project management positions at Quintiles and Q-Med/Galderma, with experience from a range of indications within drug and medical device development.

MARKUS THORHead of Business DevelopmentHoldings: 0 shares, 0 warrants

MBA from Stockholm School of Economics and M.Sc. in Chemistry from UmeåUniversity. 25 Years of experience in the pharmaceutical industry with positions within business development and R&D including Vice President & Head of Business Development at Biovitrum AB, Chief Business Officer at Kancera AB and Senior Scientist at Pharmacia.

40

Overview of LIDDS’ patent portfolio

PATENT PATENT US EU REST OF THE WORLD

1 / 2004 Bioceramic compositions Approved Approved Not filed

2 / 2006 Method to treat prostate cancer Approved ApprovedAus, Can, Chi, Jap, Mex, Russ, S Kor, Nor, Afr, Isr, Ind,

3 / 2007 Slow local drug release Approved ApprovedAus, Can, Chi, HK, Jap, Mex, Russ, S Kor, Isr, S. Afr, Ind,

4 / 2009 Mixing tool suspensions Approved ApprovedAus, Can, Chi, Russ, Isr, Jap, Mex, S Korea, Ind, S. Afr

5 / 2009 Steering of curing Approved ApprovedAus, Can, Russ, Jap, HK, Mex, S.Kor, Ind, Isr, S. Afr

6 / 2016 Manufacturing process Approved Approved -

7 / 2017 NanoZolid + STING - Filed -

A. APPENDIX

41

Monica Wallter, CEO LIDDS [email protected]

Thank you!

MANAGEMENT PRESENTATION - Lidds...15 Source: (1) World Cancer Research Fund, 2018, (2) Cancer...

Documents

Transcript of MANAGEMENT PRESENTATION - Lidds...15 Source: (1) World Cancer Research Fund, 2018, (2) Cancer...